Focal Areas of High Signal Intensity in Children with Neurofibromatosis Type 1: Expected Evolution on MRI

References

1. 1.↵
   2. Nicita F,
   3. Di Biasi C,
   4. Sollaku S, et al

   . Evaluation of the basal ganglia in neurofibromatosis type 1. Childs Nerv Syst ChNS Syst 2014;30:319–25 doi:10.1007/s00381-013-2236-z pmid:23892392

   CrossRefPubMed
2. 2.↵
   2. Lopes Ferraz Filho JR,
   3. Munis MP,
   4. Soares Souza A, et al

   . Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1. Pediatr Radiol 2008;38:305–10 doi:10.1007/s00247-007-0712-x pmid:18231788

   CrossRefPubMed
3. 3.↵
   2. North KN,
   3. Riccardi V,
   4. Samango-Sprouse C, et al

   . Cognitive function and academic performance in neurofibromatosis 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997;48:1121–27 doi:10.1212/wnl.48.4.1121 pmid:9109916

   FREE Full Text
4. 4.↵
   2. DiPaolo DP,
   3. Zimmerman RA,
   4. Rorke LB, et al

   . Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995;195:721–24 doi:10.1148/radiology.195.3.7754001 pmid:7754001

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Billiet T,
   3. Mädler B,
   4. D'Arco F, et al

   . Characterizing the microstructural basis of “unidentified bright objects” in neurofibromatosis type 1: a combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis. Neuroimage Clin 2014;4:649–58 doi:10.1016/j.nicl.2014.04.005 pmid:24936416

   CrossRefPubMed
6. 6.↵
   2. Ferner RE,
   3. Chaudhuri R,
   4. Bingham J, et al

   . MRI in neurofibromatosis 1: the nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 1993;56:492–95 doi:10.1136/jnnp.56.5.492 pmid:8505641

   Abstract/FREE Full Text
7. 7.↵
   2. Hyman SL,
   3. Gill DS,
   4. Shores EA, et al

   . T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry 2007;78:1088–91 doi:10.1136/jnnp.2006.108134 pmid:17299016

   Abstract/FREE Full Text
8. 8.↵
   2. Payne JM,
   3. Pickering T,
   4. Porter M, et al

   . Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18-year study. Am J Med Genet A 2014;164:661–65 doi:10.1002/ajmg.a.36338

   CrossRef
9. 9.↵
   2. Feldmann R,
   3. Schuierer G,
   4. Wessel A, et al

   . Development of MRI T2 hyperintensities and cognitive functioning in patients with neurofibromatosis type 1. Acta Paediatr Oslo Paediatr 2010;99:1657–60 doi:10.1111/j.1651-2227.2010.01923.x pmid:21039823

   CrossRefPubMed
10. 10.↵
    2. Ottenhoff MJ,
    3. Rietman AB,
    4. Mous SE

    , ENCORE-NF1 Team, et al. Examination of the genetic factors underlying the cognitive variability associated with neurofibromatosis type 1. Genet Med 2020;22:889–97 doi:10.1038/s41436-020-0752-2 pmid:32015538

    CrossRefPubMed
11. 11.↵
    2. Itoh T,
    3. Magnaldi S,
    4. White RM, et al

    . Neurofibromatosis type 1: the evolution of deep gray and white matter MR abnormalities. AJNR Am J Neuroradiol 1994;15:1513–19 pmid:7985572

    Abstract/FREE Full Text
12. 12.↵
    2. Kraut MA,
    3. Gerring JP,
    4. Cooper KL, et al

    . Longitudinal evolution of unidentified bright objects in children with neurofibromatosis-1. Am J Med Genet A 2004;129A:113–19 doi:10.1002/ajmg.a.20656 pmid:15316979

    CrossRefPubMed
13. 13.↵
    2. Menor F,
    3. Marti-Bonmati L,
    4. Arana E, et al

    . Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur J Radiol 1998;26:121–31 doi:10.1016/S0720-048X(97)00088-0 pmid:9518221

    CrossRefPubMed
14. 14.↵
    2. Raininko R,
    3. Thelin L,
    4. Eeg-Olofsson O

    . Non-neoplastic brain abnormalities on MRI in children and adolescents with neurofibromatosis type 1. Neuropediatrics 2001;32:225–30 doi:10.1055/s-2001-19115 pmid:11748492

    CrossRefPubMed
15. 15.↵
    2. DiMario FJ,
    3. Ramsby G

    . Magnetic resonance imaging lesion analysis in neurofibromatosis type 1. Arch Neurol 1998;55:500–05 doi:10.1001/archneur.55.4.500 pmid:9561977

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Gill DS,
    3. Hyman SL,
    4. Steinberg A, et al

    . Age-related findings on MRI in neurofibromatosis type 1. Pediatr Radiol 2006;36:1048–56 doi:10.1007/s00247-006-0267-2 pmid:16912896

    CrossRefPubMed
17. 17.↵
    2. Khan A,
    3. Beri S,
    4. Baheerathan A, et al

    . Globus pallidus high-signal lesions: a predominant MRI finding in children with neurofibromatosis type 1. Ann Indian Acad Neurol 2013;16:53–56 doi:10.4103/0972-2327.107702 pmid:23661963

    CrossRefPubMed
18. 18.↵
    2. Griffiths PD,
    3. Blaser S,
    4. Mukonoweshuro W, et al

    . Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential? Pediatrics 1999;104:e49 doi:10.1542/peds.104.4.e49 pmid:10506274

    Abstract/FREE Full Text
19. 19.↵
    2. Yamanouchi H,
    3. Kato T,
    4. Matsuda H, et al

    . MRI in neurofibromatosis type I: using fluid-attenuated inversion recovery pulse sequences. Pediatr Neurol 1995;12:286–90 doi:10.1016/0887-8994(95)00045-H pmid:7546002

    CrossRefPubMedWeb of Science
20. 20.↵
    2. von Elm E,
    3. Altman DG,
    4. Egger M, et al

    . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–57 doi:10.1016/S0140-6736(07)61602-X

    CrossRefPubMedWeb of Science
21. 21.↵
    Neurofibromatosis: Conference Statement—National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575–78 pmid:3128965

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Ferraz-Filho JR,
    3. José da Rocha A,
    4. Muniz MP, et al

    . Unidentified bright objects in neurofibromatosis type 1: conventional MRI in the follow-up and correlation of microstructural lesions on diffusion tensor images. Eur J Paediatr Neurol 2012;16:42–47 doi:10.1016/j.ejpn.2011.10.002 pmid:22088602

    CrossRefPubMed
23. 23.↵
    2. DeBella K,
    3. Poskitt K,
    4. Szudek J, et al

    . Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 2000;54:1646–51 doi:10.1212/wnl.54.8.1646 pmid:10762507

    Abstract/FREE Full Text
24. 24.↵
    2. Sevick RJ,
    3. Barkovich AJ,
    4. Edwards MS, et al

    . Evolution of white matter lesions in neurofibromatosis type 1: MR findings. AJR Am J Roentgenol 1992;159:171–75 doi:10.2214/ajr.159.1.1609692 pmid:1609692

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Aoki S,
    3. Barkovich AJ,
    4. Nishimura K, et al

    . Neurofibromatosis types 1 and 2: cranial MR findings. Radiology 1989;172:527–34 doi:10.1148/radiology.172.2.2501822 pmid:2501822

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Campian J,
    3. Gutmann DH

    . CNS tumors in neurofibromatosis. J Clin Oncol 2017;35:2378–85 doi:10.1200/JCO.2016.71.7199 pmid:28640700

    CrossRefPubMed
27. 27.↵
    2. Spyris CD,
    3. Castellino RC,
    4. Schniederjan MJ, et al

    . High-grade gliomas in children with neurofibromatosis type 1: literature review and illustrative cases. AJNR Am J Neuroradiol 2019;40:366–69 doi:10.3174/ajnr.A5888 pmid:30573459

    Abstract/FREE Full Text
28. 28.↵
    2. Dangouloff-Ros V,
    3. Roux C-J,
    4. Boulouis G, et al

    . Incidental brain MRI findings in children: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2019;40:1818–23 doi:10.3174/ajnr.A6281 pmid:31624116

    Abstract/FREE Full Text
29. 29.↵
    2. Kakeda S,
    3. Korogi Y,
    4. Hiai Y, et al

    . Pitfalls of 3D FLAIR brain imaging: a prospective comparison with 2D FLAIR. Acad Radiol 2012;19:1225–32 doi:10.1016/j.acra.2012.04.017 pmid:22818791

    CrossRefPubMed